Prospect News: News for Medicines Co.

E-mail us: service@prospectnews.com Or call: 212 374 2800

Bank Loans - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products

Add to balance / Manage account

Not logged in

Prospect News home > Main news index > All issuers starting with M > Issuers starting with M, CV only > All stories on Medicines Co. > Stories on Medicines Co., CV only

Search again

Enter part or all of the issuer name:

Market:

All markets No structured products Bank loans Canadian bonds CLOs Convertibles Distressed debt Emerging markets High yield Investment grade Liability management Municipals PIPEs Preferreds Private placements All leveraged markets Structured products

Market: BK = Bank loans, CV = Convertibles, DD = Distressed Debt, EM = Emerging Markets, HY = High Yield, IG = Investment Grade, LM = Liability Management, MU = Municipals, PP = PIPEs, PF = Preferreds, PV = Private Placements, SP = Structured Products
Recent items, highlighted in orange, are $4.00 each. All others are $1.00 each. Headlines in gray are not currently covered by your subscription.

Medicines Co.

1/6/2020	CVLM	Medicines announces make-whole fundamental change for convertibles
12/31/2019	CV	Outlook 2020: Convertible returns hit 20%; outperformance expected to continue in 2020
11/25/2019	CV	Market Commentary: Medicines convertibles in focus on buyout; Intercept expands; Liberty Media improves
11/25/2019	CV	Market Commentary: Morning Commentary: Medicines convertibles in focus on buyout; broader secondary quiet
11/20/2019	CV	Market Commentary: Chefs’ Warehouse edges up; Fluidigm prices $50 million deal; Pinduoduo tanks outright
11/20/2019	CV	Market Commentary: Morning Commentary: Chefs’ Warehouse edges up; Fluidigm on tap; Medicines off highs
11/19/2019	CV	Market Commentary: Medicines convertibles gain; Intelsat tumbles; Chefs’ Warehouse planned notes eyed
9/3/2019	CV	Market Commentary: Convertibles primary active: Insulet, Zillow, Okta, Aerie Pharma, Encore launch deals
8/30/2019	CV	Market Commentary: Convertibles ‘firm’ ahead of holiday; Western Digital tops actives list; Workday drops
8/30/2019	CV	Market Commentary: Morning Commentary: Convertibles ‘firm’ ahead of holiday; lower stocks weigh outright
8/28/2019	CV	Market Commentary: Medicines convertible extends gains; Fortive, Proofpoint active ahead of U.S. holiday
8/28/2019	CV	Market Commentary: Morning Commentary: Medicines 2.75% convertibles gain; Fortive, Proofpoint notes active
8/27/2019	CV	Market Commentary: Medicines trades actively; Momo quiet despite share move; convertibles mostly steady
8/26/2019	CV	Market Commentary: Fortive active; Medicines pops on trial data; Tesla 2% notes slightly higher with stock
6/4/2019	CV	Market Commentary: Altair, Q2 Holdings, New Mountain on tap; JPMorgan Voya-linked notes, Veoneer active
1/17/2019	CV	Market Commentary: Aurora Cannabis convertibles offering eyed; Energizer flat; Ligand sees slight rebound
1/14/2019	CV	Medicines greenshoe fully exercised; ups 3.5% notes to $172.5 million
1/4/2019	CV	Market Commentary: Ensco convertible notes eyed as crude oil futures bounce; Medicines sees large seller
1/4/2019	CV	Medicines greenshoe ups 3.5% five-year convertibles to $163 million
12/14/2018	CV	Market Commentary: Medicines prices convertibles; outstanding issues come in; short-duration better bid
12/14/2018	CV	Market Commentary: Morning Commentary: Medicines prices new convertible notes; outstanding issues come in
12/14/2018	CV	New Issue: Medicines prices $150 million five-year convertible notes to yield 3.5%, up 27.5%
12/13/2018	CV	Market Commentary: Market eyes Medicines convertible offering; Wayfair in focus; Macquarie sees big seller
12/13/2018	CV	Market Commentary: Morning Commentary: Market eyes Medicines convertible offering; primary quiet otherwise
12/12/2018	CV	Market Commentary: Medicines on tap; Neurocrine Biosciences expands; Splunk tops par; Tilray yield crosses 11%
12/12/2018	CV	Medicines talks $150 million five-year convertibles to yield 3%-3.5%, up 25%-30%
7/11/2018	CV	Market Commentary: Sempra’s convertible preferreds trade up; Palo Alto, Twitter in focus; biotech active
12/21/2017	CV	Market Commentary: Focus shifts to new year; Cobalt dominates; Medicines gains; Seacor holders don’t wait on put
10/25/2017	CV	Market Commentary: Cobalt sister convertibles bounce off lows; Nabors down; Shutterfly adds; Weibo deal on deck
10/25/2017	CV	Market Commentary: Morning Commentary: Cobalt International Energy convertibles in mid-teens, off lows as shares sag
8/30/2017	CV	Market Commentary: Convertibles mostly name driven; Ctrip.com trades up with shares; Medicines moves around
8/30/2017	CV	Market Commentary: Morning Commentary: Convertibles mostly name driven; Medicines trading action in focus
7/25/2017	CV	Market Commentary: Novavax loses ground; Pacira trial results disappoint; Medicines’ data positive, bonds flat
3/20/2017	CV	Market Commentary: Tesla’s new issue remains in focus; Viavi ticks up; Medicines rebounds from Friday lows
3/20/2017	CV	Market Commentary: Morning Commentary: Tesla’s new issue remains in focus; Viavi ticks up; Medicines rebounds
3/17/2017	CV	Market Commentary: Tesla’s new deal in focus, comes ‘under pressure’; ON’s recent deal does ‘OK’; Medicines falters
3/17/2017	CV	Market Commentary: Morning Commentary: Convertibles market focuses on new Tesla deal; ON firms; Medicines falters
2/6/2017	CV	Market Commentary: Convertibles see positive tone; Greenbrier adds 3 points since issue; Medicines extends gains
2/3/2017	CV	Market Commentary: Convertible bond market continues to eye earnings; FireEye paper weakens; Weatherford firms
1/6/2017	CV	Market Commentary: Biotech sector firm, led by Medicines, Ionis; Pandora convertibles in decline; Colony dips
1/6/2017	CV	Market Commentary: Morning Commentary: Biotech sector firm, led by Medicines, Ionis; Pandora convertibles in decline
11/16/2016	CV	Market Commentary: Weatherford, AMD gain; Endologix drops sharply; Medicines up; PDL BioPharma deal on tap
11/16/2016	CV	Market Commentary: Morning Commentary: Weatherford gains; Medicines up after trial data; planned PDL BioPharma eyed
11/8/2016	CV	Market Commentary: Priceline convertibles rise on earnings beat; Depomed misses; Medicines mixed; Iconix steady
11/8/2016	CV	Market Commentary: Morning Commentary: Priceline convertibles rise on earnings beat; Depomed misses; Medicines mixed
10/6/2016	CV	Market Commentary: Twitter, Salesforce convertibles reverse courses as takeover talk eyed; Medicines retreats
10/6/2016	CV	Market Commentary: Morning Commentary: Twitter, Salesforce.com reverse course amid takeover talk; Medicines retreats
7/19/2016	CV	Market Commentary: Convertibles trade quietly amid mixed stocks; Medicines lower with shares; Intel eyed
7/19/2016	CV	Market Commentary: Morning Commentary: Convertibles trade quietly amid trendless stocks; Medicines a bit lower
7/11/2016	CV	Market Commentary: Convertible bond investors stick with the usual suspects; EZCorp rises; Medicines better
6/10/2016	CV	Market Commentary: New Tutor Perini convertible expands on swap as shares rally; MTS Systems sells mandatory
6/10/2016	CV	Medicines greenshoe exercise increases convertibles to $402.5 million
6/8/2016	CV	Market Commentary: New Nevro trades up out of the chute, shares higher; Tutor Perini launches new issue
6/7/2016	CV	Market Commentary: New Medicines convertible notes gain on swap; planned Nevro looks cheap; Zillow jumps
6/7/2016	CV	Market Commentary: Morning Commentary: New Medicines’ trades up on swap; Zillow convertibles jump on settlement news
6/7/2016	CV	New Issue: Medicines prices $350 million seven-year convertibles to yield 2.75%, up 32.5%
6/6/2016	CV	Market Commentary: Planned Medicines’ $350 million deal looks ‘fair’; Weatherford expands; Nevro on tap
6/6/2016	CV	Market Commentary: Morning Commentary: Medicines launches $350 million convertibles; Weatherford moves higher
6/6/2016	CV	Medicines to price $350 million seven-year convertibles at 2.5%-3%, up 27.5%-32.5%
2/17/2016	CV	Market Commentary: Planned Invacare deal looks cheap; Priceline 0.9% convertibles contract with higher shares
1/20/2016	CV	Market Commentary: Convertibles ‘for sale’ as equities fall; Stone Energy drops to 55, Fluidigm to below 50
1/11/2016	CV	Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
1/11/2016	CV	Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
12/31/2015	CV	Outlook 2016: Modest convertible returns expected, but vol. should boost valuations; rates eyed
11/3/2015	CV	Market Commentary: AMAG Pharmaceuticals tumbles outright on earnings miss; Priceline edges up; Ctrip in line
10/8/2015	CV	Market Commentary: SanDisk adds on swap; Icahn gets tenders for 68% of Vivus bonds; SunEdison stays in focus
10/8/2015	CV	Market Commentary: Morning Commentary: Ctrip.com pulls back after gains earlier in week; Medicines extends losses
9/18/2015	CV	Market Commentary: Convertibles quiet, steady post Fed; some health-care names better bid; Medicines edges up
9/18/2015	CV	Market Commentary: Morning Commentary: Convertibles quiet post Fed; valuations steady; Medicines trades flat to higher
9/1/2015	CV	Market Commentary: Convertibles quiet amid equity sell-off; Yahoo! resilient in risk-off trade; Medicines up
9/1/2015	CV	Market Commentary: Morning Commentary: Convertibles quiet amid steep equity sell-off; Medicines extends gains
8/31/2015	CV	Market Commentary: Medicines expands on swap on positive drug data; energy names hesitate on oil’s reversal
8/31/2015	CV	Market Commentary: Morning Commentary: Medicines convertibles expand on swap on positive drug trial data; Yahoo! adds
7/7/2015	CV	Market Commentary: Medicines higher in active trade; Depomed deflects Horizon offer; Ctrip off its lows
7/7/2015	CV	Market Commentary: Morning Commentary: Medicines convertibles higher in active trade; Depomed deflects Horizon offer
4/13/2015	CV	Market Commentary: Clovis jumps outright, on swap; Medicines, Horizon Pharma trade; Asian internet names eyed
1/13/2015	CV	Medicines greenshoe lifts 2.5% seven-year convertibles to $400 million
1/9/2015	CV	Market Commentary: Brocade convertibles expand on swap; equities swoon again; convertibles ‘better for sale’
1/8/2015	CV	Market Commentary: Medicines adds on hedge in busy trade; Resource Capital slips from discounted offer price
1/8/2015	CV	Market Commentary: Morning Commentary: Medicines adds on hedge; Resource Capital slips from discounted offer price
1/8/2015	CV	New Issue: Medicines prices upsized $350 million seven-year convertibles to yield 2.5%, up 35%
1/7/2015	CV	Market Commentary: Medicines adds, Resource Capital slips in gray market; Brocade launches $500 million deal
1/7/2015	CV	Market Commentary: Morning Commentary: Planned Medicines convertibles look cheap; Resource Capital also on tap
1/7/2015	CV	Medicines to price $300 million seven-year convertibles to yield 2.5%-3%, up 32.5%-37.5%
1/6/2015	CV	Market Commentary: Red Hat, NXP Semiconductors improve; U.S. Steel gains; Medicines, Resource Capital on tap
1/6/2015	CV	Medicines to price $300 million seven-year convertibles to yield 2.5%-3%, up 32.5%-37.5%
10/28/2014	CV	Market Commentary: Twitter drops outright, mixed to lower on hedge; Medicines opens up; Synergy to price
7/23/2014	CV	Market Commentary: Earnings spur activity; Xilinx drops outright, expands on hedge; Cubist adds on hedge
4/1/2014	CV	Market Commentary: Midday Commentary: Medicines expands on hedge after disappointing court opinion; McDermott eyed
4/1/2014	CV	Market Commentary: Medicines expands on hedge after court opinion; McDermott nearly flat in gray market
2/14/2014	CV	Market Commentary: Midday Commentary: New, upsized Akamai trades slightly over par; secondary market quiet
2/14/2014	CV	Market Commentary: Upsized Akamai trades slightly over par; Tesla 'has improved'; Frontline little changed
2/13/2014	CV	Market Commentary: Imperial gains in modest trade; planned Akamai sees par bid; Medicines expands on hedge
2/10/2014	CV	Market Commentary: Midday Commentary: Xilinx convertibles flat after being called; Medicines down mostly in line
2/10/2014	CV	Market Commentary: AMAG Pharmaceuticals offers $150 million deal; Xilinx 3.125% notes steady; Medicines down
6/14/2012	CV	Medicines greenshoe exercised, lifts convertibles to $275 million
6/7/2012	CV	Market Commentary: NorthStar prices at discount; Navistar comes in on slashed guidance; Molina improves
6/6/2012	CV	Market Commentary: New Medicines Co. 'does well' as shares slip; Navistar in line before earnings; NetApp busy
6/6/2012	CV	New Issue: Medicines Co. details upsized $225 million convertibles, priced to yield 1.375%, up 22.5%
6/5/2012	CV	Medicines Co. plans $200 million of five-year convertibles to yield 1.125%-1.625%, up 20%-25%
6/5/2012	CV	New Issue: Medicines Co. prices $225 million of five-year convertibles to yield 1.375%, up 22.5%
6/5/2012	CV	Market Commentary: Central European drops on restatement news; Illumina comes in slightly; Medicines Co. on tap

©2025 Prospect News. This page is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies, faxing, photocopying or any other form of reproduction.